Is NF-κB a good target for cancer therapy? Hopes and pitfalls

By Véronique Baud, M. Karin. Nature reviews. Drug discovery, 2009

964 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Apoptosis and Molecular Targeting Therapy in Cancer (2014, background): “Conflict of Interests The authors declare that there is no conflict of interests regarding the publication of this paper.”
STATs in cancer inflammation and immunity: a leading role for STAT3 (2009, positive): “Because of its ability to induce the expression of a large array of inflammatory mediators and its role as a core transcription factor in diverse immune responses, nuclear factor-κB (NF-κB) signalling has been recognized as a major pathway responsible for both inflammation-induced carcinogenesis and”
Autophagy and the integrated stress response (2010, neutral): “(Baud and Karin, 2009).”